Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
Fiche publication
Date publication
février 2016
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Grimaud JC, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B,
Lien Pubmed
Résumé
Ustekinumab, a human monoclonal antibody against the p40 subunit of interleukins-12 and -23, is effective in inducing and maintaining remission in patients with luminal Crohn's disease (CD). We assessed the efficacy and safety of subcutaneous ustekinumab in patients with anti-tumor necrosis factor (anti-TNF) refractory CD.
Mots clés
Adult, Crohn Disease, drug therapy, Europe, Female, Humans, Immunologic Factors, adverse effects, Injections, Subcutaneous, adverse effects, Male, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor-alpha, therapeutic use, Ustekinumab, adverse effects
Référence
Clin. Gastroenterol. Hepatol.. 2016 Feb;14(2):242-50.e1-2